

1 **MINUTES OF THE MEETING**
2 **OF THE PQRI PSD MASS BALANCE WORKING GROUP ON**
3 **5 August 2003**

4 **I. PARTICIPANTS**

Terry Tougas (Boehringer Ingelheim), Chair	Lana Lyapustina (IPAC-RS)
Dave Christopher (Schering-Plough)	Jolyon Mitchell (Trudell Medical)
Paul Curry (USP Aerosols Expert Committee)	Brian Rogers (FDA)
Ken Furnkranz (FDA)	Helen Strickland (GlaxoSmithKline)

5 **II. OPENING**

6 Dr. Tougas welcomed the participants and reviewed the objectives of the meeting: (i) to
7 discuss feedback from the PQRI Workshop's presentation; (ii) to review final GCIP proofs; (iii)
8 to comment on the draft Letter to the Editor summarizing results of the recent survey on
9 MB/ APSD failures; (iv) to discuss the Milestones Check chart; and (v) to agree on next steps.

10 The participants reviewed the draft minutes of the meeting on 24-25 September 2002,
11 agreed on a number of word changes and approved the revised minutes.

12 **III. DISCUSSION**

13 Dr. Mitchell reviewed the Letter to the Editor of the Journal, Aerosol Medicine. The
14 participants offered some editorial revisions and approved the draft Letter. They also
15 recommended that a summary of the survey's results be posted on the PQRI website in some
16 form. Dr. Mitchell agreed to draft such a summary.

17 The Working Group reviewed the Milestones Check chart and noted that the delays in
18 carrying out certain planned activities are due to the lack of data submissions and volunteer
19 laboratories for the CI experiment. The participants requested that this issue be discussed by
20 the senior PQRI committees. In addition, Dr. Tougas agreed to contact companies individually
21 to solicit support for these data-gathering efforts.

22 **IV. AGREED**

- 23 • Dr. Mitchell will make the changes to the draft Letter to Editor, Journal of Aerosol
24 Medicine, and the Letter will be forwarded for further PQRI review. Dr. Mitchell
25 will also draft a summary of the survey results for posting on the PQRI website.
- 26 • The Steering Committee will be approached to advise on the issue of data. In
27 addition, a letter will be drafted to solicit industry involvement in the CI variability
28 experiment and the data mining. Dr. Tougas will contact individual companies to
29 request their participation in these data-gathering efforts.

30 **V. NEXT TELECONFERENCE / MEETING**

31 The date of the next teleconference will be confirmed by email.

32 *Finalized on 10 October 2003*